Clinical Trial Spotlight: Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)

Dr. Marlise Luskin, a specialist in the Adult Leukemia Program at Dana-Farber Cancer Institute, explains an innovative trial that combines the BCL2 inhibitor, venetoclax with chemotherapy for older patients with ALL. For more information about this trial, visit:

Related Presenters

Marlise Luskin, MD, MSCE.

Marlise Luskin, MD, MSCE

Assistant Professor of Medicine, Harvard Medical School

Dr. Luskin received her MD from the University of Pennsylvania Perelman School of Medicine in 2009. She completed residency training in Internal Medicine at Brigham and Women's Hospital, followed by a fellowship in Hematology and Oncology ...

View full profile

Related Videos